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Simple Summary: Prostate cancer is the third most frequent cancer in men worldwide, with a
notable increase in prevalence over the past two decades. The PSA is the only well-established
protein biomarker for prostate cancer diagnosis, staging, and surveillance. It frequently leads to
inaccurate diagnosis and overtreatment since it is an organ-specific biomarker rather than a tumour-
specific biomarker. As a result, one of the primary goals of prostate cancer proteome research is to
identify novel biomarkers that can be used with or instead of PSA, particularly in non-invasive blood
samples. Thousands of peptides or assays were detected in blood samples from patients with low- to
high-grade prostate cancer and healthy individuals, allowing data processing of sequential window
acquisition of all theoretical mass spectra (SWATH-MS). By assisting in the detection of prostate
cancer biomarkers in blood samples, this useful resource will improve our understanding of the role
of proteomics in prostate cancer diagnosis and risk assessment.
Abstract: Prostate cancer is the most frequent form of cancer in men, accounting for more than
one-third of all cases. Current screening techniques, such as PSA testing used in conjunction with
routine procedures, lead to unnecessary biopsies and the discovery of low-risk tumours, resulting
in overdiagnosis. SWATH-MS is a well-established data-independent (DI) method requiring prior
knowledge of targeted peptides to obtain valuable information from SWATH maps. In response to the
growing need to identify and characterise protein biomarkers for prostate cancer, this study explored
a spectrum source for targeted proteome analysis of blood samples. We created a comprehensive
prostate cancer serum spectral library by combining data-dependent acquisition (DDA) MS raw files
from 504 patients with low, intermediate, or high-grade prostate cancer and healthy controls, as well
as 304 prostate cancer-related protein in silico assays. The spectral library contains 114,684 transitions,
which equates to 18,479 peptides translated into 1227 proteins. The robustness and accuracy of the
spectral library were assessed to boost confidence in the identification and quantification of prostate
cancer-related proteins across an independent cohort, resulting in the identification of 404 proteins.
This unique database can facilitate researchers to investigate prostate cancer protein biomarkers
in blood samples. In the real-world use of the spectrum library for biomarker detection, using a
signature of 17 proteins, a clear distinction between the validation cohort’s pre- and post-treatment
groups was observed. Data are available via ProteomeXchange with identifier PXD028651.
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1. Introduction
Prostate cancer (PCa) is the third most prevalent malignant tumour in the world,
accounting for 7.3% of all cancer-related incidence rates and 3.8% of all cancer-related
fatalities in 2020 [1]. The European Association of Urology (EAU-ESTRO-SIOG) [2] cur-
rently recommends analysing serum concentrations of prostate-specific antigen (PSA)
with accompanying digital rectal examination (DRE) and multiparametric Magnetic Res-
onance Imaging (mpMRI) [3]. While PSA levels are age-stratified for diagnosis [4,5] its
expression is organ-specific rather than tumour-specific and is frequently associated with
non-neoplastic aetiology; likewise, DRE is insensitive [6]. Detection is typically related to
unnecessary biopsies, which decide the final diagnosis by histological examination of the
prostate gland. Biopsies are an invasive procedure that has an elevated risk of post-biopsy
complications [7]. D’Amico categorised PCa risk stratification using PSA levels, TNM
(tumour, nodes, and metastases), and histology (Gleason Score), which are widely utilised
in clinical practice [8]. Nonetheless, there remains a clinical need for biomarkers to improve
PCa diagnosis, patient stratification, and clinical outcome prediction.
Alternatively, new potential PCa biomarker panels are presently being investigated,
and their application will ideally reshape the way clinical decision making is conducted
in the future. The PHI (Prostate Health Index), PCA3 (Prostate Cancer Antigen 3) and
Prolaris tests, for example, have been approved by the US Food and Drug Administration
(FDA), whereas the Clinical Laboratory Improvement Amendments (CLIA) have accepted
the 4Kscore panel algorithm, Mi-Prostate score (MiPS), OncotypeDx, ConfirmMDx, and
Decipher [3,9]. The majority of the time, they are used in combination for clinical deci-
sion making about initial and repeated biopsies as well as monitoring therapy outcomes;
nevertheless, no single biomarker appears to be superior to PSA.
Traditionally, clinical diagnostics relied heavily on antibody-based detection tech-
niques, which had limitations. There has recently been a considerable amount of evidence
of study in biomarker identification using high throughput technology. Mass spectrometry
(MS) is a powerful tool that allows for a thorough understanding of the proteome aberra-
tions of the complex biological matrix with disease development. It has been extensively
used for the development of new biomarkers in a variety of cancer types [10–13]. Al-
though genomics and transcriptomics analyses have potential, not all genetic abnormalities
are readily converted into disease phenotypes [14]. Conversely, protein molecules are
appropriate representations of disease progression and serve as active targets for cancer
therapeutics [15].
SWATH-MS (sequential window acquisition of all theoretical fragment-ion spectra
mass spectrometry) is a data-independent acquisition (DIA) approach for ionising and
fragmenting all peptides in a biological sample. The precursor and product ions are
separated by an orderly and impartial series of predefined precursor isolation windows [16].
All precursor and product ions data will be permanently logged in a single scan within
the specified mass range, requiring a targeted data extraction approach. This technique is
based on a sample-specific spectral reference library containing all the peptides obtained
from DIA data. As a result, reference libraries are essential to the success of SWATH-MS
studies [17].
Here, we offer a bespoke spectral library for SWATH-MS based measurement of
circulatory proteins produced in the blood of PCa patients to aid and improve PCa blood-
based biomarker discovery.
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2. Results
2.1. Characteristics of the Study Participants
Serum samples from 373 PCa patients with abnormal prostate on digital rectal exami-
nation, symptomatic presentation with high PSA levels and abnormal biopsies, or patients
with a significant rise in PSA associated with urinary symptoms were used to create the
library (Table S1). Serum samples were also taken from 134 healthy control subjects with
normal DRE and PSA levels of less than 1 ng/mL (1 ng/mL). The cancer group was older
(p value = 0.01) with an average age of 67.57 ± 7.48 compared to 65.48 ± 10.22 in the control
group (Figure 1A). The BMI of both groups lay within the same range with no statistical
difference, 26.37 ± 3.48 and 27.19 ± 4.24 for the cancer and control group, respectively
(Figure 1B). PSA levels in the cancer patients were significantly higher than in the control
group (p value ≤ 0.0001) with mean PSA of 13.19 ± 93.52 and 0.97 ± 0.514, respectively
(Figure 1C). The majority of patients in the cancer group presented with a Gleason score
of 6, whereas the number of patients with a Gleason score of 7, 8 and 9 is small (Figure 1D).
The majority of the PCa patients exhibited T1 and T2 staged tumours with occasional cases
of T3 stage along with nodal invasion and metastasis (Table S1).
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The in silico spectral library contained 41,995 transitions, 4503 peptides, and 346 pro-
teins. The consensus library of serum PCa built on the Lumos instrument contained 83,346 
transitions, 9577 peptides, and 760 proteins, whereas the consensus library built on the 
Sciex-TOF 6600 in micro-flow and nano-flow contained 50,160 transitions, 6210 peptides, 
484 proteins, and 36,624 transitions, 4478 peptides, and 712 proteins, respectively. The in-
corporation of all consensuses and in silico libraries into a comprehensive PCa serum li-
brary yielded 114,684 transitions, 13,793 peptides, and 1227 unique proteins. Table 1 dis-










0 10 20 30 40 50 0 40 80 14020











Figure 1. De ographic and clinical characteristics of PCa patients (n = 373) and healthy male volunteers (n = 134) used
for spectral library generation. (A) Age distribution; (B) body mass index; (C) prostate-specific antige (in ng/mL); and
(D) Gleason score frequency dis ribution. All haracteristics were captured at the time of sample collection. Statistical
significance was determined by a non-parametric Man –Witney test. p value shown as: 0.01–0.05 (*) and <0.001 (****).
2.2. The Spectral Libraries
The in silico spectral library contained 41,995 transitions, 4503 peptides, and 346 pro-
teins. The consensus library of seru PCa built on the Lu os instru ent contained 83,346
transitions, 9577 peptides, and 760 proteins, hereas the consensus library built on the
Sciex-T F 6600 in icro-flo an ano-flo contained 50,160 transitions, 6210 peptides,
484 proteins, and 36,624 transitions, 4478 eptides, and 712 proteins, respectively. The
incorporation of all consensuses and in silico libraries into a comprehensive PCa serum
lib ar yiel ed 114,684 transitions, 13,793 peptides, and 1227 unique proteins. Table 1
displays the assay stati tics for each acquired library.
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Table 1. Details of the in silico (Disease), in-house built PCa spectral libraries acquired at Orbitrap
Fusion Lumos Tribrid (Thermo Scientific, Waltham, MA, USA) mass spectrometer (in micro-flow
mode) (Lumos), Sciex TripleTOF 6600 mass spectrometer in micro-flow mode (S-Micro) and nano-
flow mode (S-Nano) and combined library (Combined-PCa) built after the integration all four, using
an online tool, iSwathX (at protein FDR of 1%). S-Micro was used as base library and others added
on in the process of integration.


























The average number of peptides per protein in the in silico disease-associated library
was six, and the average length of peptides was 15 amino acids (Figure S2). A minor
percentage of the precursor ions (0.07%, 30) was singly charged. Approximately 54.6%
(22,944) of precursor ions was doubly charged, 35.1% (14,760) had a charge of 3, 8.2%
(3450) had a charge of 4, 1.4% (666) had a charge of 5, and 0.3% (132) had a charge of 6.
All proteins included were proteotypic; hence, the existence of shared proteins was not
observed (Figure 2A). In respect of the distribution of fragment, types that presented y-ions
were more frequently observed (82%, 34,572) compared to b-ions (18%, 7422) (Figure 2A).
The average number of peptides per protein for Lumos library was approximately nine,
with an average length per peptide of 15 amino acids. The total number of proteotypic
proteins was 561 and shared proteins was 199 (Table S2). The percentage of double and
triple charged precursor ions was 63% (52,722) and 37% (30,624), respectively, whereas the
percentage of y-ions was predominant at 83% of total ions (69,153) compared to b-ions
(17%, 14,193) (Figure 2B). For the S-nano library, the frequency distribution of precursor
charge was doubly charged at 41% (or 15,012), triply charged at 59% (or 21,612 in total),
and ion type was: y-ions; 81% or 29,524 in total; b-ions, 19% (or about 7100 in total), similar
to the generated Lumos library (Figure 2D). The average number of peptides per protein
was five, with a mean count of 15 amino acids per protein. The total count of proteotypic
and shared proteins was 508 and 204, respectively. The library acquired on Sciex TOF 6600
instrument on micro-flow mode resulted in the lowest number of total proteins identified
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484; out of them 136 were shared. The average peptides identified per protein were eight
with a mean length of 15 amino acids and precursor charge distribution of 0.01% (6), 52%
(26,196) and 48% (23,958) for the single, double, and triple charge, respectively (Figure 2C).
In parallel to other spectral libraries, y-ions (82%, 40,883) were also predominant in the
S-micro library compared to b-ions (18%, 9277) which were observed in a smaller amount
(Figure 2C). The precursor ion m/z ranged for samples run on Sciex-TOF 6600, and Lumos
was between 399 to 1249 m/z, which corresponds well to the MS mass range settings for
the full coverage of peptides through SWATH analysis (Figure S2). The product ion m/z
ranged between 350–1499 m/z for samples run on Sciex (in micro-flow and nano-flow),
which went between 350–1998 m/z for samples run on Lumos (Figure S2).
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Figure 2. er i l li raries generated in silico and built in-house. Frequency distribution of eptides
per protein and ion per peptides of (A) in silico library (Disease); (B) in-house library built on Orbitrap Fusion Lumos
Tribrid Thermo Scientific (Waltham, MA, USA) mass spectrometer (in micro-flow mode); (C) in-house library built on Sciex
TripleTOF 6600 mass spectrometer (in micro-flow mode, S-Micro); (D) in-house library built on Sciex TripleTOF 6600 mass
spectrometer (in nano-flow mode, S-Nano); (E) retention time (RT) correlation between the four libraries by using S-micro
as a base library; (F) Venn diagram presenting the proteotypic proteins overlap between the four libraries.
For integrating all in-house built libraries into a comprehensive PCa serum library,
retention time correlation was determined by taking S-micro as the base library. The
reason behind the selection of S-micro as base library was the similarity between the MS
settings for the data acquisition for DDA and the SWATH-MS analysis. The retention
time correlation (R2) between S-micro with Disease, Lumos and S-nano library was 0.98
(Figure 2E). The overlap between proteotypic proteins of the four libraries showed 200
proteins unique to disease library, 182 unique to S-nano, 181 unique to Lumos library and
13 unique to S-micro (Figure 2F, and Table S2). Overall, acquisition of data at micro-flow
coupled with DDA offered the lowest amount of exclusivity and coverage compared to
nano-flow coupled DDA mode.
Cancers 2021, 13, 5580 6 of 20
2.3. Integrated PCa Serum Spectral Library
Assay statistics for the combined library are given in Table 1, and full characterisation
is presented in Figure 3. The precursor charge distribution showed the abundance of pre-
cursor charge 2 (55%, 63,618) followed by precursor charge 3 (41%, 47,448; Figure 3A). The
remaining charged species (charge 1 = 0.03%, 36; charge 4 = 2.5, 28,989; charge 5 = 0.6%, 624;
charge 6 = 0.11, 132) were less prevalent. Similarly, y-ions (83%, 95,630) were predominant
compared to b-ions (17%, 19,138; Figure 3B). The precursor m/z charge ranged between
399–1248 m/z and the product charge between 350–1873 m/z (Figure S2). The frequency
distribution of peptides per protein presented an average of 7 peptides per protein, and the
mean amino acid count per peptide was 15 (Figure S2). The total protein count comprised
1227 (950 were proteotypic; Table S2).
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The use of gene ontology to classify proteotypic proteins revealed that the majority
of proteins are present in extracellular areas and that their biological and molecular roles
are abundant in regulatory, structural, and binding properties, influencing cellular and
metabolic processes. (Figure 3C).
A comparison of proteotypic proteins in the combined-PCa library with the Pan-Human
library [18] (one of the most comprehensive spectral libraries covering over 10,000 human
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proteins), revealed 154 proteins unique to the combined-PCa library (Figure 4A) that were
enriched in cancer and hormonal signalling pathways (Figure 4B). These proteins include the
previously identified PCa marker KLK isoforms (KLK2, KLK11) as well as the products
of additional PCa-related genetic markers such as TNF, MYC, BRCA2, and ERG1. Tissue
origin in serum proteome studies has not in general provided clear indication of organ
involvement. Nevertheless, we examined this using the Human Protein Atlas and the 154
unique protein list. Of these proteins, KLK2, TMEFF2, SPDEF, GPRC6A, ANO7, ALOX15B,
SLC45A3, PAGE4 and TRPM8 are prostate-specific, while PTGS2 is ductus deferens and
seminal vesicle specific, BRCA2, GGN, ZNF233, CAGE1, HSD17B3, ZSCAN5B, GAGE2A,
PHOX2A, ARGFX, ESR2, DBX1, ART3, TERT and SHC4 are testis-specific. Organ asso-
ciations for the complete list of 154 proteins identified using the combined PCa library
is shown in Table S3. In Figure S3, we presented the protein-protein interactions of 154
different entities. Furthermore, the total protein content of the combined-PCa serum library
was compared to other PCa-related libraries obtained from the literature (built on different
sample types) (Figure 4C). Liu et al. identified 548 proteins in a spectrum library with shot-
gun measurements of 22 non-aggressive (Gleason score 5–7) and 11 aggressive (Gleason
score 8–9) pooled prostate tissue samples obtained from PCa patients after surgery [19].
Garrido-Rodriguez et al. discovered 2558 proteins by using pooled samples of human
PCa cell lines DU145, LNCaP, PC-3, and 22Rv1 to generate a spectral library through a
shotgun approach [20]. When these two libraries were compared to our combined library,
we discovered a total of 959 distinct proteins in our combined-PCa serum library (Table
S4). The cell-lines library found 2442 different proteins, but the prostate tissue library dis-
covered the fewest (364). Our combined-PCa collection has reported the most PCa-related
circulatory proteins and the most comprehensive coverage of the PCa blood proteome, to
the best of our knowledge.
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Raw data files from the validation cohort were analysed against the combined-PCa 
serum spectral library. CV was calculated to assess the technical variation across all bio-
logical samples used for validation and was found to be less than 10, which is consistent 
with the possibility of technical variation (Figure 5A). One of the most challenging issues 
in quantifying the serum proteome is the dynamic range of proteins present, which makes 
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Furthermore, 1% of all human gene mutations have been linked to cancer development.
Germline mutations account for 20% of all mutations, with somatic mutations accounting
for the remainder [21]. To identify proteins associated with tumours or tumorigenesis,
we compared a list of 569 genes from the catalogue of somatic mutations in the cancer
(COSMIC) database acquired from the Human Protein Atlas to a list of genes (acquired
from Uniprot IDs) from our combined library to assess if there was any overlap. We
discovered 64 genes that were shared by both sources, yet 886 were unique to the combined
PCa library and 499 were unique to the COSMIC database (Table S5).
2.4. Spectral Library Validation
An independent cohort of PCa patients’ serum samples was used for library validation.
The patient cohort included pre-treated patients (n = 29) with rising PSA levels who
needed treatment, as well as patients who had undergone treatment (n = 14) who received
brachytherapy/radiotherapy (T1 and T2 staged patients), external beam radiotherapy
when diagnosed with urinary complications (T3 staged patients; Table S6). The average
difference in PSA before and after treatment was 11.91 ± 24.68 and 5.47 ± 6.79, respectively.
Raw data files from the validation cohort were analysed against the combined-PCa
serum spectral library. CV was calculated to assess the technical variation across all
biological samples used for validation and was found to be less than 10, which is consistent
with the possibility of technical variation (Figure 5A). One of the most challenging issues
in quantifying the serum proteome is the dynamic range of proteins present, which makes
measurement difficult. Since the serum proteome is usually occupied by highly abundant
proteins, measuring low abundance proteins is difficult. Immune depletion of the key
abundant proteins is one approach to addressing this issue. We report the dynamic range
of the PCa serum proteome after depleting the 12 most abundant proteins and ranking
all 404 identified proteins in the validation cohort by their log mean intensity based on
their abundance (Figure 5B). The PCa proteome is six orders of magnitude higher than
the typical dynamic range of serum or plasma reported in the literature (this lies within
2–4 log range). The dynamic ranges of individual proteins detected in the PCa serum
validation cohort were then calculated using the ratio of the maximum and minimum log10
protein intensities (Figure 5C). The identified proteins had dynamic range values ranging
from 2.07 to 6.57 (SD = 0.85) orders of magnitude. True targets were estimated using a
target-decoy approach, which identified 5572 transitions, 4953 peptides, and 404 proteins
with an FDR of 1% (Figure 5D) (Table S7). Table S8 shows the sum of transitions, peptides,
and proteins across each sample from the validation cohort.
For the real-world application of the spectrum library in biomarker identification,
the separation between the validation cohort’s pre- and post-treatment groups was as-
sessed using a random forest model after elucidating the significant entities demonstrating
discrimination between the two groups. This resulted in a list of 17 proteins including;
APOM (p value = 0.00080582), TTR (p value = 0.0010406), APOH (p value = 0.001424),
SAA4 (p value = 0.0026501), CA1 (p value = 0.0054433), ITGB3 (p value = 0.0054809), SER-
PINA6 (p value = 0.007307), BCHE (p value = 0.0078392), SERPINA4 (p value = 0.019909),
C8B (p value = 0.030581), LUM (p value = 0.031786), CRTAC1 (p value = 0.038456),
AZGP1 (p value = 0.047812), FN1 (p value = 0.15521), ENO2 (p value = 0.21444), MINPP1
(p value = 0.7663) and BTD (p value = 0.98711), indicating that the pre- and post-radiotherapy
samples were well separated (Figure 6A,B, Table S9). To improve the separation of the
pre- and post-radiotherapy samples, highly variable proteins (ITGB3) and proteins with
non-significant p values (FN1, ENO2, MINPP1, and BTD) were removed from the heatmap.
This further demonstrated that the pre- and post-radiotherapy samples clustered differently
based on the selected proteins (Figure 6C).
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cally boost the expression of KLKB1 (average intensity = 16.05) serine proteases that 
demonstrate unregulated expression in PCa. Other biomarkers were overexpressed as 
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Following that, we investigated the ability of the spectral library to quantify six PCa
biomarker candidates previously reported in the literature across the validation cohort.
We chose plas a kallikrein (KLKB1), Myc proto-oncogene protein (MYC), insulin-like
growth factor I (IGF1), Src proto-oncogene tyrosine-protein kinase Src (SRC), breast cancer
type 1 susceptibility protein (BRCA1), and signal transducer and activator of transcrip-
tion 3 (STAT3). PSA (KLK3, a widely used clinical biomarker for PCa) was shown to
dramatically boost the expression of KLKB1 (average intensity = 16.05) serine proteases
that demonstrate unregulated expression in PCa. Other biomarkers were overexpressed
as well (MYC = 8.5, IGF1 = 10. 8, SRC = 10.75, BRAC1 = 9.78, STAT3 = 12.05), albeit
not as significantly as KLKB1 (F gure 7A). Finally, we wanted to evalu te the amount of
expression of proteins that bind to PSA in order to demonstrate the ref rence library’s
additional applications. PSA attach s to one of three proteins found n serum: alph -1
antitrypsin, alpha-1 antichymotrypsin, and alpha-2 macroglobulin. We determined the
mean expression of these PSA binding pr eins throughout o r vali at on cohort samples
o be 21.22, 20.78, and 19.34 for alpha-1 antitrypsin, alpha-1 antichymotrypsin, and alpha-2
macrog obulin, respectively (F ure 7B).
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pathophysiological state, the concentrations of these can span a 10 order of magnitude, 
making the profiling of these difficult when using modern LC-MS/MS methods [22]. Be-
cause the most abundant proteins in blood account for 99% of total protein content, re-
ducing them would increase the dynamic range of the serum and increase the visibility of 
the less abundant proteins, which are more likely to serve as markers and accurate indi-
cators of an individual's physiological status [23]. 
To increase the signal-to-noise ratio when building bespoke spectral libraries from 
clinical samples several strategies can be employed. First, one may be able to adopt a pool-
ing strategy, grouping the samples in sub-pools to increase the probability to detect low 
abundance proteins or putative “sample-specific proteins” as our group has previously 
undertaken in other studies [24]. However, this current study has been performed in se-
rum samples and not in proximal fluids. The latter may have a more diverse proteome, or 
more precisely, a proteome enriched in proteins derived from specific organs. For serum 
samples we adopted an alternative strategy relying on a deep fractionation of the samples 
and analysis on three different instruments. Using a deep fractionation will help to over-
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The emphasis in PCa clinical research has shifted away from single biomarker anal-
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proved diagnosis and risk classification. The detection of low abundance proteins using 
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3. Discussion
Blood is a highly complex bodily fluid composed of cellular and biochemical compo-
nents separated from serum after removing the cells and clotting factors. Human serum is
an easily accessible, non-invasive source for biomarkers and the proteome within presents
a profile of proteins originating from normal and damaged cells, tissues, and organs. While
the dynamic levels of these circulatory proteins may correlate with an individual patho-
physiological state, the concentrations of these can span a 10 order of magnitude, making
the profiling of these difficult when using modern LC-MS/MS methods [22]. Because
the most abundant proteins in blood account for 99% of total protein content, reducing
them would increase the dynamic range of the serum and increase the visibility of the less
abundant proteins, which are more likely to serve as mark rs and accur te indicators of an
individu l’s physiological status [23].
T i i l - is ti il i tr l li ri s f
clinical samples several strategies can be employed. First, one may b able to adopt a
pooling strategy, grouping the samples in sub-pools to increase the probability to detect
low abundance proteins or putative “sample-spe ific proteins” as our group has previously
un ert t ies [24]. However, this current study has been perfo med in serum
sa ples and not i proximal fluids. The latt r may have a more div rse p oteome, r more
precisely, a proteome enrich d in proteins der ved from specific organs. For serum samples
we adopted an alternativ strategy elying on a deep fractiona of the samples and
analysis on three different ins ruments. U ing a deep fractionation will help to overcome
the major hurdle of s rum proteomics, which is t e pr sence of few, yet highly abunda t
proteins (albumin, globulins, inflamm tion-related proteins) [25]. Additionally, the use of
different instrumentation and set-ups will increase the ion diversity of the spectral library,
in turn increasing the number of peptides and proteins. The combination of the spectral
libraries obtained from the Orbitrap and Q-TOF instruments showed a much larger number
of consensus proteins eventually included in the combined PCa serum library.
The emphasis in PCa clinical research has shifted away from single biomarker analysis
and toward the identification of panels of biomarkers [26]. Researchers are constantly striv-
ing to create novel proteome biomarkers in non-invasive biological matrices for improved
diagnosis and risk classification. The detection of low abundance proteins using new and
powerful MS platforms in conjunction with depletion techniques to offer full coverage of
proteome aberrations in response to disease states has been a significant achievement in
proteomics. SWATH-MS is one such tool that enables the comprehensive and permanent
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storing of information about peptides and their fragmented species within a specific m/z
range [16]. Prior knowledge in a reference spectral library is necessary to extract data from
permanent digital maps utilising a peptide-centric technique [17]. We present a complete
online database of 1227 proteins associated with serum samples from PCa patients and
healthy individuals (controls) to facilitate PCa blood-based proteomics for clinical research
(Table 1, Figure 3).
This study comprehensively covers the serum proteome matrix by utilising a variety
of LC workflows (nano and micro-flow) and instrument types (Table 1, Figure 2). Microflow
separations are commonly performed at flow rates of less than 100 µL/min [27], whereas
nano-flow separations are accomplished at flow rates as low as a few nL/min [28]. The
normalised retention time added dimensionless value to both LC setups employing iRT
peptides. Comparing the two workflows on the Triple TOF 6600 revealed a significant
variation in the overall number of proteins detected, which was 484 and 712, respectively.
Micro-flow discovered 68 unique proteotypic proteins, and nano-flow identified 228 unique
proteotypic proteins. This reveals that a nano-LC workflow covers the biological matrix
more thoroughly than a micro-flow approach on a similar device. However, micro-flow
can avoid time-consuming column blockage and can maximise sample throughput, as a
result, it is the preferred approach in clinical proteomics. It has already been established
that a spectrum library constructed using TripleTOF data identifies fewer proteins than one
constructed using Orbitrap data [29]. The comparison of nano-LC workflows on TOF 6600
and Orbitrap also revealed an increase in the total number of proteins identified (n = 760)
in the latter.
The clinical characteristics of the PCa patients included in this study ranged from low-
risk indolent cancer to high-risk nodal invasion and metastasis (Table S1, Figure 1), allowing
for the establishment of a comprehensive blood proteomic database for extensive PCa
research in early and late staged PCa. SWATH reference libraries previously created for the
assessment of PCa samples focussed on tissues and cell lines [19,30–32]. However, a major
hurdle in using biomarkers based on tissue is whether this will result in a non-invasive
clinical diagnosis [7] and whether the cell lines are real representations of cancer which
are modelling [33]. As a result, blood and other readily accessible biofluids have become
the future of biomarker research. In a study using PCa serum samples, the researchers
created a pan-human plasma spectrum library that contained 1151 plasma glycoproteins
originating from five solid tumours, including PCa [34]. To the best of our knowledge, the
library presented here is the first dedicated spectral library to analyse PCa blood proteome.
The PCa serum spectral library contains a diverse collection of extracellular proteins
involved in metabolic, physiological, developmental, and signalling activities (Figure 3).
Comparing our PCa-serum spectrum library to the pan-human spectral library [18], a
comprehensive proteome database of plasma, tissue, and cell line samples, revealed 154
proteins unique to our PCa-serum collection (Figure 4). Among these are proteins asso-
ciated with carcinogenesis, enriched in cancer-related signalling pathways, and proteins
involved in hormone signalling. TNF [35], BRCA2 [36], MYC [37], and IL6 [38] are some
examples of proteins that are frequently associated with PCa and are also known to func-
tion as biomarkers for other types of cancer. While comparing the total protein content of
our PCa serum library to that of other PCa-related tissue and cell line reference libraries
revealed 959 proteins unique to serum samples. This demonstrates the critical nature of
having a sample-specific reference library for extending the coverage of information in
SWATH maps and enhancing the clinical utility of SWATH-MS in blood-based proteomics
of PCa.
Our strategy was to include a large number of patients in the cohort used to construct
the library in order to increase the diversity and heterogeneity of the clinical samples in-
cluded. As such, 75% of all patients enrolled for this study were comprised in the discovery
cohort for library building. An independent cohort of pre-radiation and post-radiation PCa
patients was used to determine the utility and technical validity of the PCa-serum spectral
library. A total of 404 proteins in the SWATH maps with a 1% FDR have been identified,
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with a good dynamic range and coverage compared to other relevant studies, which found
272 and 249 proteins on SWATH blood proteome tests of five solid carcinomas [34] and
pulmonary cancer [39] respectively. Separation across clinical conditions was also evident
using the top significant proteins, which increase the clinical utility of the spectral library
in real-world experiments (Figure 6). Our rationale for including different patients in
the validation cohort was to keep this validation independent from the discovery cohort.
Testing on all available samples may result in overestimation of the library’s performance.
By evaluating the performance of our library blindly in an independent group of samples,
we established the first step toward analysis of larger cohorts of patients. As we have
now established a robust, bespoke library for the community we will perform validation
analyses as other cohorts become available.
The KLKB1 gene codes for the production of a protein known as pre-kallikrein that
is produced in the liver and circulates in the blood and is involved in blood clotting [40].
MYC mRNA and protein overexpression in PCa tumour foci corresponds with disease
severity [37]. IGF1, a downstream MAPK and PI3K receptor, boosts their signalling and
promotes the formation of PCa [41]. The recurrence of castration-resistant PCa is influenced
by androgen receptor signalling [42]. BRCA genes have been linked to breast and ovarian
cancer. They also raise the risk factors for aggressive PCa in men because cells are less
capable of repairing DNA damage without BRCA genes, making them more vulnerable
to tumour formation [43]. Similarly, STAT3 and its upstream activator, the IL6 receptor,
have been linked to PCa development and may represent future therapeutic targets [44].
We confirmed the expression of PCa-related proteins across SWATH maps of validation
cohort samples to establish the utility of our reference library for biomarker research
(Figure 7A). PSA enters the bloodstream free or bound to one of three serum proteins: α-2
macroglobulin, α-1-antichymotrypsin and α-1antitrypsin. PSA appears to be abundant in
bound form in PCa males, indicating that PCa cancer cells produce more of these binding
proteins [45]. We validated that they were included in the PCa validation set (Figure 7B).
This study shows a comprehensive range of PCa serum peptide assays and may aid
in quantifying low, moderate, and high-grade PCa. Improved blood-based biomarkers
are of critical clinical importance to provide improved, non-invasive diagnoses that will
likely replace PSA. The novel TMPRSS2-ERG gene mRNA and PCA3 genetic marker are
already being utilised in clinical practice, but it is unclear if the resulting protein alterations
affect disease progression and treatment response [26]. As a result, proteome research
is still required for biomarker identification to be possible. While a SWATH-MS-based
analysis may allow for rapid differentiation of cancer and non-cancer samples, it is unlikely
to be easily converted into routine clinical practise. However, it may pave the way for
developing clinically manageable immunoassay-based technologies.
4. Materials and Methods
4.1. Research Ethics and Approval
This study was approved by Yorkshire and the Humber-Leeds East Research Ethics
Committee under reference no. 08/H1306/115+5 and IRAS project ID 3582. All study
participants submitted written consent prior to the collection of blood samples. All personal
data pertaining to participants were kept strictly confidential and processed in accordance
with the Data Protection Act (1998). The inclusion criteria for samples from PCa patients
are abnormal DRE, rising PSA levels, symptomatic patients with urinary symptoms, and
histological confirmation of PCa, while the criteria for their matched controls are normal
DRE, PSA 1ng/mL, asymptomatic individuals with no urinary symptoms, and no detection
of PCa on histological analysis.
4.2. Sample Collection
Peripheral blood was collected into red-capped BD Vacutainer®blood collection tubes
(BD Biosciences, Wokingham, UK) from 373 newly diagnosed PCa patients and 134 healthy
male individuals, used as controls. Vacutainers containing blood were inverted five times
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and incubated at room temperature for 30 min before centrifugation at 3000 rcf (g) for
10 min. The clear fraction of serum was further stored at −80 ◦C until analysis. All samples
were processed within 2 hours of collection. The serum samples from PCa patients and
healthy controls were pooled separately for library generation (Figure 8).
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pipeline, X!Tandem was utilised for database search of raw MS files. The in silico library was created by extracting PCa-
related proteins from the Disease database using a z-score cut-off of 5.0. iSwathX, a web-based tool, was used to merge all
four assay libraries.
4.3. Sample Preparation
To maximise the epth of prot ome penetration, pooled PCa and healthy control
samples were processed using PierceTM top 12 abundant protein depletion spin c lumns
followi g the manufacturer’s recommen ations (Thermo Fisher Scientific, Loughborough,
UK. Concentr tion a d p rification of depleted serum samples were performed using
Amicon®ultra-0.5 centrifugal filter devices (Cat #: UFC5003BK, Sigma-Aldrich, Merck
KGaA, Darmstadt, Germany). To reduce the salt concentration in the serum samples, they
were subjected to a buffer exchange with 25 mM ammonium bicarbonate (Sigma-Aldrich,
Merck KGaA, Darmstadt, Germany). The total protein content of concentrated serum sam-
ples was quantified using the bicinchoninic acid assay (BCA test, Thermo Fisher Scientific,
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Loughborough, UK). The total protein concentration was then normalised to 60 µg per
140 µL of sample using 25 mM ammonium bicarbonate, 35 µL LDSx4 (Cat #: NP0007,
Invitrogen, Thermo Fisher Scientific, Loughborough, UK), 10 mM dithiothreitol (Cat #:
17-1318-02, GE HealthCare Life Sciences, Amersham, UK), and 1% sodium deoxycholate
(Cat #: 75746-250g, Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) and denatured for
2 min at 95 ◦C. Cell lysates were cooled at room temperature. Proteins were alkylated by
adding 750 mM iodoacetamide (Cat #: I1149-25g, Sigma-Aldrich, Merck KGaA, Darmstadt,
Germany) (Final concentration 50 mM) to a final volume of 150 µL and incubating at room
temperature in the dark for 20 min with intermittent mixing.
4.4. In-Gel Fractionation
Gel fractionation was performed by putting 70 µL of reaction mix per well into a
10-well Bolt NuPAGE 4–12% Bis-Tris gel (Invitrogen, Cat #: NW04120BOX) and running
at 200 Volts for 22 min in MES Buffer. It was soaked in Instant Blue (Sigma, Darmstadt,
Germany, Cat #: 1SB1L) dye for 15 min to stain the gel. The gel was divided horizontally
into ten equal-sized strips (Figure S1) and then vertically, with the lanes of each protein
sample serving as a guide. Using a clean scalpel, the gel slices were then transferred to
the wells of a 96-well plate. To sufficiently destain, the pieces were repeatedly washed
with 50 mM ammonium bicarbonate and 50 mM ammonium bicarbonate/50% acetonitrile.
Each washing cycle took 10 min on a shaking rotator. After the final wash, the gel pieces
were dried for 10 min at 50 ◦C in a centrifugal evaporator.
4.5. In-Gel Tryptic Digestion
Gel fragments were submerged in 150 µL of 50 mM ammonium bicarbonate/10%
(v/v) acetonitrile containing 5 ng/µL trypsin and centrifuged (1000× g) for 1 min at 4 ◦C,
followed by 30 min on ice. To ensure that all gel components were entirely immersed,
wells were topped up with 50 mM ammonium bicarbonate and incubated overnight at
37 ◦C. The tryptic peptides were extracted by repeatedly adding 10% (v/v) formic acid
in acetonitrile to each sample. Each wash was followed by the transfer of supernatant
containing peptides to a non-Lobind 96-well plate and vacuum drying at 55 ◦C. Dried
peptides were kept at −20 ◦C until further analysis was required.
4.6. Data Dependent Acquisition (DDA) Analysis
To generate the library, dried peptides were reconstituted in 5% acetronitrile/0.1%
formic acid, 10 fmol/µL Pep-CalMix (Cat #: 5045751, A B Sciex, Warrington, UK), and 10×
iRT (Biognosys AG, Schlieren, Switzerland, in a 50:1 ratio). The LC-MS was loaded with
reconstituted samples for nano- and micro-flow DDA analysis. Nano analysis (Eksigent,
Dublin, CA, USA) was performed using an Acquity uPLC M-Class, C-18 column (Waters,
Part No: 186007484) with a flow rate of 300 nL/min and a runtime of 87 min. Microanalysis
was performed using an analytical column—YMC-Triart C18 column (YMC Europe GmbH,
Dinslaken, Germany, S/N 17019) with a flow rate of 5 µL/min and a run time of 87 min.
The LC gradients for nano- and micro-flows were composed of 0.1% formic acid/LC-MS
grade water and 0.1% formic acid/acetonitrile. DDA analysis was carried out on a Sciex
Triple TOF 6600 Mass Spectrometer (AB Sciex, Warrington, UK) using a nano-flow source
with a 5 µL injection volume and a 300 nL/min flow rate for nano-flow analysis and a
microflow duospray source with a 10 µL injection volume and a 5 µL/min flow rate for
microflow analysis. For both analyses, the TOF-MS mass range was 400–1250 Da, and
the product ion mass range was 100–1500 Da [46]. Additionally, 5 µL (~1 µg) of each
reconstituted sample was loaded on a 10 cm fused silica AcclaimTM PepMapTM 5 µm 100
Nano-Trap Column (Thermo Fisher Scientific, Loughborough, UK) using a U3000 RSLC
high-pressure nanoLC (Dionex, Cambereley, UK) as described by Njoku et al. Eluting
peptides were quantified using a Thermo Scientific Orbitrap Fusion Lumos Tribrid mass
spectrometer operating in DDA mode [24].
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4.7. Building the SWATH Spectral Library
All LC-MS/MS raw data (.wiff/.wiff.scan) files obtained from the Sciex Triple TOF
6600 Mass Spectrometer were searched against the UniProtKB/Swiss-Prot database of
20,271 reviewed, non-redundant protein species (without isoforms) (Accessed 17 December
2015), supplemented with iRT peptides, and decoy sequences using X!Tandem (Version
PILEDRIVER—1 April 2015). Before searching against the database, the raw data (.raw)
files collected from the Orbitrap Fusion Lumos Tribrid mass spectrometer were converted
to the mzXML format and centroided. The database search was performed using the
default X!Tandem parameters [17] with few adjustments as described in Njoku et al.,
2021. To generate the libraries, SpectraST was used in conjunction with the OpenSWATH
workflow to obtain the consensus libraries in .TSV format. The FDR of each assay library
was adjusted to 1% using a target-decoy database. To facilitate use of our spectral library by
other researchers, we utilised relatively standard OpenSWATH settings and included only
b and y ions which were generally the most intense and a minimum of 6 fragment ions per
peptide. We limited the maximum number of ions per peptide to 6 in order to extract the
most intense transitions for inclusion in the SWATH assay library (Code: spectrast2tsv.py
-l 350,2000 -s b,y -x 1,2 -o 6 -n 6 -p 0.05 -d -e -w ). This setting permits the incorporation
of all y and b ion series especially y10 or y11, but only if they are particularly intense
and observable. Previous investigations in our laboratory have demonstrated that these
settings have no effect on quantification when a larger number of less intense ions are
included [24]. To generate the in silico library, a list of proteins associated with PCa was
collected from the Jensen lab’s “Disease database” [47], using a z-score cut-off of 5.0. For
the list of PCa-related proteins, information regarding their peptides and fragments was
raised via a synthetic human proteome database [48] and/or repository of 10,000 human
proteins [18]. Using the default parameters, iSwathX (version 2.0) [49] was utilised to create
an extended reference library by integrating all four bespoke spectral libraries. The base
library was collected on a Sciex instrument in micro-flow mode, and the remaining libraries
were added by combining the protein accession numbers and deleting any redundancy.
The following information was added: “transition name” and “transition group id” to
the combined library using a R script (R version 4.0.2). The combined consensus library’s
.TSV format was converted to Transition Markup Language (TraML) format using the
TargetedFileConverter tool, and then decoys were added using the OpenSwathDecoyGenerator
tool with an identity threshold of 1 and a similarity level of 0.05 Da. The combined assay
library in TraML format was used for downstream SWATH analysis.
4.8. SWATH-MS Data Acquisition and Library Validation
The library was validated using LC-MS/MS analysis on serum samples from PCa
patients using a TripleTOF 6600 linked to a Micro HPLC system (Sciex, Warrington, UK).
Serum samples from PCa patients were prepared using immunodepletion, protein concen-
tration/buffer exchange, reduction/alkylation, and tryptic digestion. For analysis on the
SWATH platform, dried tryptic peptides were reconstituted in a mixture of loading buffer
(2% acetonitrile/0.1% formic acid), pepcalmix (10 fmol/µL, SCIEX, Warrington, UK), and
index retention time (iRT) peptides (2X) (Biognosys AG, 8952 Schlieren, Switzerland) [16].
The analytical column was a YMC-Triart C18 12 nm, 3 m, 0.3 mm I.D. X 150 mm, 1/32” col-
umn (YMC Europe GmbH TA12S03-15HORU), whereas the trap column was a YMC-Triart
C18 12 nm, S-3 m, 5 X 0.5 mm I.D., 1/32” column (YMC Europe GmbH TA12S03-15HORU)
(YMC Europe GmbH TA12S03-E5JORU). The capacity of the sample pickup was set at 8 µL
at a flow rate of 5 µL/min. The data were acquired using the 100 variable window method
in conjunction with MS parameters; accumulation time was 0.249 s, the m/z range was
400–1250, the period was 119.98 min, the cycles were 2572, the delay time was 0 s, and the
cycle time was 2.799 s [39].
Raw data files (.wiff) were searched against a combined purpose-built PCa serum
library using openSWATH (version 2.0.0) [50]. PyProphet (version 0.18.3) [51] was used
to score the peptide matches, and the results were aligned using the MSproteomicstools
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feature alignment [52]. Potential contaminants and decoy sequences were deleted before
to conducting any analyses. An m-score threshold of 0.01 was utilised to annotate and
filter the feature alignment file using the SWATH2Stats tool (Bioconductor packages re-
lease 3.11) [53]. The data were converted into a format that MSstats (Bioconductor packages
release 3.11) [54] could interpret. The data were processed by selecting the ‘top3’ feature
subset and then normalising the resulting information with the function “equalizeMedi-
ans.” The summaryMethod was set to “TMP,” the cutoffCensored to “minFeature,” and no
missing data imputation was performed. In the acquired protein quants, all “NA” values
were replaced with “0.” Random Forests (RF) were used to choose features, with data
split 70:30 (training/testing) and ntree set to 1000 (Rstudio version 4.0.2). The gene ontol-
ogy study was carried out using WebGestalt [55]. KEGG pathways and protein-protein
interactions were investigated using the STRING database [56].
5. Conclusions
This study created a broad-spectrum PCa serum reference library by combining data
from different LC technologies (micro-LC and nano-LC) and MS equipment. Additionally,
PCa-related proteins were incorporated in silico to aid in developing biomarkers for
PCa detection and surveillance. It is capable of processing clinical data acquired during
SWATH-MS/DIA operations utilising a variety of high-resolution instruments. This library
contains previously described blood and tissue biomarkers and a large number of proteins
that are not identified in Pan-Human, PCa tissue, or cell-line reference libraries. This
is the most comprehensive PCA-serum library accessible, with around 13,793 peptides
and 1227 proteins. It identified 404 serum proteins in a validation dataset, indicating the
library’s appropriateness for the purpose for which it was designed. It can be combined
with other publicly accessible PCa-related tissue reference libraries to provide researchers
with a complete picture of PCa proteome dynamics. With an increasing demand for
novel biomarkers, this library provides an opportunity to identify clinically useful PCa
biomarkers.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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well 5 contained SeeBlue™ Plus2 Pre-stained Protein Standard, well 7 and 8 contained (70 µL each)
pooled serum samples from 134 healthy men used as control. The band size of each markers’ band is
given in parallel (in KDa), Figure S2: Distribution of peptide length (red dotted line represents amino
acid cut-off of 15), peptides per protein, product charge (m/z) and precursor charge (m/z) for each
consensus library used in this study, Figure S3: An outline of protein-protein interactions between
proteins specific to the combined-PCa serum library when compared against the Pan-Human library
based on a STRING database analysis, Table S1: Demographic and clinical characteristics of PCa
patient cohort and healthy male volunteers used for generation of spectral library, Table S2: List
of proteotypic/non-shared proteins identified across in silico disease library and in-house built
spectral libraries acquired on Orbitrap Fusion Lumos Tribrid and Sciex TOF 6600 mass spectrometer
coupled with micro and nano LC columns, Table S3: Tissue specificity of 154 proteins unique to
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Overlap of the total protein count of our combined serum PCa serum spectral library and PCa spectral
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et al.), Table S5: To identify proteins associated with tumours or tumorigenesis, we compared a
list of 569 genes from the catalogue of somatic mutations in cancer (COSMIC) database acquired
from the Human Protein Atlas to a list of genes (acquired from Uniprot IDs) from our combined
library, Table S6: Clinical characteristics of PCa patient cancer validation cohort of pre and post
treatment radiotherapy samples used for validation of spectral library, Table S7: Assay characteristics
of validation cohort following analysis against PCa serum spectral library, Table S8: Assay statistics
across each validation sample after analysing them against PCa serum spectral library, Table S9. List
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